Cardiovascular events and all-cause mortality: effects of dual therapy intensification with insulin vs glucagon-like peptide-1 analogue

被引：0
|
作者：
Anyanwagu, U. [1 ]
Mamza, J. [1 ]
Mehta, R. [2 ]
Donnelly, R. [1 ]
Idris, I. [1 ]
Idris, I. [1 ]
机构：
[1] Univ Nottingham, Div Med Sci & Grad Entry Med, Nottingham NG7 2RD, England
[2] Univ Nottingham, Trent Res Design Serv, Nottingham NG7 2RD, England
来源：
DIABETOLOGIA | 2015年 / 58卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
937
引用
收藏
页码：S452 / S452
页数：1
相关论文
共 50 条
  • [31] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Ashish Sarraju
    Sun H. Kim
    Joshua W. Knowles
    Current Atherosclerosis Reports, 2016, 18
  • [32] The effects of glucagon-like peptide-1 on the beta cell
    Vilsboll, T.
    DIABETES OBESITY & METABOLISM, 2009, 11 : 11 - 18
  • [33] Cardiometabolic Effects of Glucagon-Like Peptide-1 Agonists
    Sarraju, Ashish
    Kim, Sun H.
    Knowles, Joshua W.
    CURRENT ATHEROSCLEROSIS REPORTS, 2016, 18 (02) : 1 - 8
  • [34] Association Between Intensification of Metformin Treatment With Insulin vs Sulfonylureas and Cardiovascular Events and All-Cause Mortality Among Patients With Diabetes
    Roumie, Christianne L.
    Greevy, Robert A.
    Grijalva, Carlos G.
    Hung, Adriana M.
    Liu, Xulei
    Murff, Harvey J.
    Elasy, Tom A.
    Griffin, Marie R.
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2014, 311 (22): : 2288 - 2296
  • [35] Effects of glucagon-like peptide-1 receptor agonists on mortality and cardiovascular events: A comprehensive meta-analysis of randomized controlled trials
    Monami, Matteo
    Zannoni, Stefania
    Pala, Laura
    Silverii, Antonio
    Andreozzi, Francesco
    Sesti, Giorgio
    Mannucci, Edoardo
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2017, 240 : 414 - 421
  • [36] Mortality and cardiovascular events in diabetes mellitus patients at dialysis initiation treated with glucagon-like peptide-1 receptor agonists
    Lai, Hsuan-Wen
    See, Chun Yin
    Chen, Jui-Yi
    Wu, Vin-Cent
    CARDIOVASCULAR DIABETOLOGY, 2024, 23 (01)
  • [37] All-cause mortality and cardiovascular outcomes with sodium-glucose Co-transporter 2 inhibitors, glucagon-like peptide-1 receptor agonists and with combination therapy in people with type 2 diabetes
    Riley, David R.
    Essa, Hani
    Austin, Philip
    Preston, Frank
    Kargbo, Isatu
    Ibarburu, Gema Hernandez
    Ghuman, Ramandeep
    Cuthbertson, Daniel J.
    Lip, Gregory Y. H.
    Alam, Uazman
    DIABETES OBESITY & METABOLISM, 2023, 25 (10): : 2897 - 2909
  • [38] Effects of gastric inhibitory polypeptide, glucagon-like peptide-1 and glucagon-like peptide-1 receptor agonists on Bone Cell Metabolism
    Hansen, Morten S. S.
    Tencerova, Michaela
    Frolich, Jacob
    Kassem, Moustapha
    Frost, Morten
    BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY, 2018, 122 (01) : 25 - 37
  • [39] Treatment of diabetes with glucagon-like peptide-1 gene therapy
    Riedel, Michael J.
    Kieffer, Timothy J.
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2010, 10 (12) : 1681 - 1692
  • [40] Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
    Zheng, Zhikai
    Zong, Yao
    Ma, Yiyang
    Tian, Yucheng
    Pang, Yidan
    Zhang, Changqing
    Gao, Junjie
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
12345